Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lowered its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 85,621 shares of the company's stock after selling 52,984 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.23% of Entrada Therapeutics worth $1,480,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in TRDA. Janus Henderson Group PLC increased its position in shares of Entrada Therapeutics by 10.5% in the third quarter. Janus Henderson Group PLC now owns 1,711,459 shares of the company's stock valued at $27,358,000 after buying an additional 161,962 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new stake in Entrada Therapeutics during the 3rd quarter worth about $1,109,000. Jacobs Levy Equity Management Inc. increased its position in Entrada Therapeutics by 50.3% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 201,803 shares of the company's stock worth $3,225,000 after purchasing an additional 67,559 shares in the last quarter. Geode Capital Management LLC increased its position in Entrada Therapeutics by 8.8% during the 3rd quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after purchasing an additional 46,512 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Entrada Therapeutics during the 3rd quarter worth about $634,000. Hedge funds and other institutional investors own 86.39% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Tuesday, February 25th. Roth Mkm assumed coverage on Entrada Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $29.00 price objective for the company. Finally, Roth Capital upgraded Entrada Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th.

Entrada Therapeutics Trading Up 0.8 %

TRDA traded up $0.08 during midday trading on Friday, hitting $10.49. The company's stock had a trading volume of 205,190 shares, compared to its average volume of 114,099. The firm has a market cap of $394.37 million, a P/E ratio of 6.60 and a beta of -0.14. The firm has a 50-day moving average price of $12.25 and a two-hundred day moving average price of $15.60. Entrada Therapeutics, Inc. has a 52-week low of $10.15 and a 52-week high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.66) by $0.69. The company had revenue of $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. On average, equities analysts expect that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.